GnRH-Antagonisten – eine neue Therapieoption beim fortgeschrittenen Prostatakarzinom

. Abstract ! At present medical castration employing luteinising hormone releasing hormone (LHRH) agonists is the standard of care for patients with advanced prostate cancer. LHRH agonists suppress the synthesis of testosterone to a castration level. In contrast to surgical castration, medical castration is reversible. However LHRH agonists induce an initial increase of the testosterone level. This so-called testosterone surge leads to tumour growth and increases the disease-specific complaints, known as flare phenomena. It may be possible that the overall survival of these patients is deteriorated. In contrast, gonadotrophin releasing hormone (GnRH) antagonists do not induce a testosterone surge and the level of testosterone decreases as rapidly as that known from a surgical castration.

[1]  Michel Bolla,et al.  [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.

[2]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[3]  K. Miller,et al.  Management of advanced prostate cancer: can we improve on androgen deprivation therapy? , 2008, BJU international.

[4]  S. Nilsson,et al.  Testosterone surge: rationale for gonadotropin-releasing hormone blockers? , 2008, Urology.

[5]  A. Orsola,et al.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. , 2007, The Journal of urology.

[6]  J. Morote,et al.  Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer , 2006, Urologia Internationalis.

[7]  J. J. de la Rosette,et al.  Degarelix: A gonadotropin-releasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients. , 2006, Journal of Clinical Oncology.

[8]  N. Lawrentschuk,et al.  Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer. , 2005, The Journal of urology.

[9]  John Trachtenberg,et al.  A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. , 2002, The Journal of urology.

[10]  D. Gleason,et al.  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. , 2001, Urology.

[11]  G. Bubley,et al.  Is the flare phenomenon clinically significant? , 2001, Urology.

[12]  M. Menon,et al.  The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. , 2001, The Journal of urology.

[13]  M. Hosaka,et al.  Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients. , 2000, Hinyokika kiyo. Acta urologica Japonica.

[14]  Jerome Seidenfeld,et al.  Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer , 2000, Annals of Internal Medicine.

[15]  D. Jocham.  Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results , 1998, Urologia Internationalis.

[16]  A. O'brien,et al.  An Evaluation of Pharmacokinetics and Pharmacodynamics of Leuprorelin Acetate 3M-Depot in Patients with Advanced and Metastatic Carcinoma of the Prostate , 1998, Urologia Internationalis.

[17]  M. T. Chen,et al.  The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. , 1994, Urology.

[18]  I. Thompson,et al.  Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. , 1990, The Journal of urology.

[19]  J. Fiet,et al.  Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). , 1989, The New England journal of medicine.

[20]  H. Kato,et al.  Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate , 2006, International Urology and Nephrology.

[21]  B. Tombal,et al.  Apoptotic pathways in prostate cancer , 2001 .